Skip to main content
[Preprint]. 2024 Feb 7:rs.3.rs-3911922. [Version 1] doi: 10.21203/rs.3.rs-3911922/v1

Table 3.

Primary study endpoint of severe (grade ≥ 3) infections

BsAb, N = 55 CAR-T, N = 92 ADC, N = 109

Infection grade 22 (40) 24 (26) 9 (8)
- grade ≥ 3 infections 2 (4) 0 1 (1%)
- grade 4 infections 4 (7) 0 0
- grade 5 infections

Recurrent severe infections 11 (20) 6 (7) 2 (2%)

n (%)

BsAb, bispecific antibodies; CAR-T, chimeric antigen receptor T-cell therapy; ADC, antibody drug conjugate.